Novartis AG

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021) Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Journal article Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany (2021) Weller K, Maurer M, Bauer A, Wedi B, Wagner N, Schliemann S, Kramps T, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study (2021) Decker T, Fasching P, Nusch A, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Examining the Association Between Self-Reported Estimates of Function and Objective Measures of Gait and Physical Capacity in Lumbar Stenosis (2021) Odonkor C, Taraben S, Tomkins-Lane C, Zhang W, Muaremi A, Leutheuser H, Sun R, Smuck M Journal article, Original article Consensus based framework for digital mobility monitoring (2021) Kluge F, Del Din S, Cereatti A, Gaßner H, Hansen C, Helbostad JL, Klucken J, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety (2021) Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, et al. Journal article, Review article Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials (2021) Fazio N, Carnaghi C, Buzzoni R, Valle JW, Herbst F, Ridolfi A, Strosberg J, et al. Journal article